SYNFLORIX is indicated for active immunization of infants and children from 6 weeks up to 5 years of age against diseases caused by Streptococcus pneumoniae serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 23F and

Safety of Synflorix was assessed in 83 HIV positive infants, 101 HIV negative infants born from an HIV positive mother and 150 children with SCD. Results suggest comparable reactogenicity and safety profile of Synflorix between these high risk groups and healthy children. PHARMACOLOGICAL PROPERTIES Pharmacodynamics

Synflorix is a vaccine that contains parts of the bacterium Streptococcus pneumoniae (, also called pneumococcus). It is used to protect infants and children aged between 6 weeks and 5 years against invasive disease, pneumonia (infection of the lungs) and acute otitis media (infection of the middle ear) caused by S. pneumoniae.

The use of Synflorix should be determined on the basis of official recommendations taking into consideration the impact on pneumococcal diseases in different age groups as well as the variability of the epidemiology in different geographical areas.

2010年6月4日 · Efficacy of SYNFLORIX against likely bacterial Community Acquired Pneumonia (CAP) was demonstrated in the according-to -protocol (ATP) cohort (immunised with at least the three-dose primary series) (p value ≤ 0,002) as the primary

second year of life in children primed with 3 doses of SYNFLORIX, lower antibody geometric mean concentration (GMC) and opsonophagocytic assay geometric mean titre (OPA GMT) were observed for one pneumococcal serotype (18 C).

Synflorix can be given concomitantly with any of the following monovalent or combination vaccines [including DTPa-HBV-IPV/Hib and DTPw-HBV/Hib]: diphtheria-tetanus-acellular pertussis vaccine (DTPa), hepatitis B vaccine (HBV), inactivated polio vaccine (IPV), Haemophilus influenzae type b

Active immunisation of infants and children from 6 weeks up to 2 years of age against invasive pneumococcal disease caused by Streptococcus pneumoniae serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F.

Official information about Synflorix from the EMA website: SPC for healthcare professionals and package leaflet for the public.

Children with impaired immune responsiveness, whether due to the use of immunosuppressive therapy, a genetic defect, HIV infection, or other causes, may have reduced antibody response to active immunization.